PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31666990-9	2019	The TGF-beta1-restored expressions of Cx43 and panx1 in osteocytes in the presence of an ERK inhibitor, U0126, further demonstrated the direct participation of Smad3/4 signalling.	U 0126	104-109	transforming growth factor beta 1	Homo sapiens	4-13	
33148869-11	2020	However, 5Z-7-oxozeaenol, SB203580 and U0126 only reversed the stimulatory effect of TGF-beta1 on ALP.	U 0126	39-44	transforming growth factor beta 1	Homo sapiens	85-94	
33025417-11	2022	Using kinase inhibitors, only U0126 treatment showed an inhibitory effect on IGF-1-reduced miR-4286 and IGF-1-induced TGFB1/TGFBR2 expressions, suggesting that MEK/ERK signaling is involved in the IGF-1/miR-4286/TGF-beta signaling axis.	U 0126	30-35	transforming growth factor beta 1	Homo sapiens	118-123	
31955434-9	2020	U0126 attenuated the TGF-beta1-induced expression/secretion of uPAR, but not PAI-1 in SCAP.	U 0126	0-5	transforming growth factor beta 1	Homo sapiens	21-30	
31807174-8	2019	Furthermore, western blot analysis confirmed that blocking the function of PI3K/Akt and ERK with LY294002 and U0126 resulted in upregulation of E-cadherin expression, and downregulation of vimentin and Snail expression in EGF- and TGF-beta1-treated HepG2 cells.	U 0126	110-115	transforming growth factor beta 1	Homo sapiens	231-240	
29261154-4	2017	RESULTS: Inhibition of ERK signaling with the MEK inhibitor U0126 blunted the ability of TGF-beta1 to induce migration in pancreatic cancer Panc1 cells.	U 0126	60-65	transforming growth factor beta 1	Homo sapiens	89-98	
30908581-7	2019	PI3K/AKT inhibitor (wortmannin) and MEK/ERK inhibitor (U0126) reduced the TGF-beta1-induced synthesis of FN, COL3, and alpha-SMA in HPFs.	U 0126	55-60	transforming growth factor beta 1	Homo sapiens	74-83	
27723266-12	2018	In addition, SB431542, 5z-7-oxozeaenol and U0126 attenuated the TGF-beta1-induced secretion of PAI-1 and suPAR.	U 0126	43-48	transforming growth factor beta 1	Homo sapiens	64-73	
30483803-3	2019	It was demonstrated that U0126 significantly inhibited the proliferation, migration and collagen contraction of HTFs stimulated with TGF-beta1.	U 0126	25-30	transforming growth factor beta 1	Homo sapiens	133-142	
30483803-4	2019	In addition, U0126 largely attenuated the TGF-beta1-induced conversion of HTFs into myofibroblasts, as indicated by a downregulation of the mRNA and protein expression of alpha-smooth muscle actin and zinc finger protein SNAI1, and by ameliorating the 3D-collagen contraction response.	U 0126	13-18	transforming growth factor beta 1	Homo sapiens	42-51	
30483803-5	2019	Mechanistically, U0126 suppressed the TGF-beta1-stimulated phosphorylation of mothers against decapentaplegic homolog 2/3, P38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2, indicating that U0126 may inhibit HTF activation through the canonical and non-canonical signaling pathways of TGF-beta1.	U 0126	17-22	transforming growth factor beta 1	Homo sapiens	38-47	
30483803-5	2019	Mechanistically, U0126 suppressed the TGF-beta1-stimulated phosphorylation of mothers against decapentaplegic homolog 2/3, P38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2, indicating that U0126 may inhibit HTF activation through the canonical and non-canonical signaling pathways of TGF-beta1.	U 0126	17-22	transforming growth factor beta 1	Homo sapiens	318-327	
30483803-5	2019	Mechanistically, U0126 suppressed the TGF-beta1-stimulated phosphorylation of mothers against decapentaplegic homolog 2/3, P38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2, indicating that U0126 may inhibit HTF activation through the canonical and non-canonical signaling pathways of TGF-beta1.	U 0126	223-228	transforming growth factor beta 1	Homo sapiens	38-47	
30483803-5	2019	Mechanistically, U0126 suppressed the TGF-beta1-stimulated phosphorylation of mothers against decapentaplegic homolog 2/3, P38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2, indicating that U0126 may inhibit HTF activation through the canonical and non-canonical signaling pathways of TGF-beta1.	U 0126	223-228	transforming growth factor beta 1	Homo sapiens	318-327	
30059670-11	2018	SIS3, U0126 and SB203580 all partly attenuated alpha-SMA mRNA expression under TGF-beta1 treatment.	U 0126	6-11	transforming growth factor beta 1	Homo sapiens	79-88	
29261154-6	2017	Basal and TGF-beta1-dependent ERK, but not SMAD activation, was blocked by U0126 in Panc1 and other cell types indicating that ERK activation is downstream or independent of SMAD signaling.	U 0126	75-80	transforming growth factor beta 1	Homo sapiens	10-19	
28779848-12	2017	Similarly, U0126 also partly inhibited the TGF-beta1-induced COX-2 expression.	U 0126	11-16	transforming growth factor beta 1	Homo sapiens	43-52	
28492136-5	2017	Afterward, treatment with the MEK1/2 inhibitor U0126 reduced the TGF-beta1-induced invasion and vimentin and MMP9 secretion in HepG2 cells, without affecting the inhibitory effects of TGF-beta1 on HepG2 cell proliferation.	U 0126	47-52	transforming growth factor beta 1	Homo sapiens	65-74	
27720345-6	2017	SB431542 and U0126 prevented the TGF-beta1-induced increase of collagen content and TIMP-1 production of dental pulp cells.	U 0126	13-18	transforming growth factor beta 1	Homo sapiens	33-42	
28959141-9	2017	h-TGF-beta1 stimulated Smad2/3 and ERK1/2 phosphorylation, and the MEK1/2 inhibitor U0126 attenuated TGF-beta1-induced KKU-M213 cell invasion and MMP-9 production but moderately enhanced the cytokine growth inhibitory activity.	U 0126	84-89	transforming growth factor beta 1	Homo sapiens	101-110	
28365272-6	2017	The levels of Smad2, Smad2/3 and ERK1/2 phosphorylation measured using western blotting confirmed that the addition of UO126 was sufficient in blocking all TGFbeta-induced ERK1/2 activation, as well as reducing Smad signaling at 18 h. Immunofluorescent labeling and further western blotting confirmed that TGFbeta-induced EMT was associated with an increase in alpha-smooth muscle actin (alpha-SMA) and a reduction of E-cadherin at cell borders.	U 0126	119-124	transforming growth factor beta 1	Homo sapiens	156-163	
28365272-6	2017	The levels of Smad2, Smad2/3 and ERK1/2 phosphorylation measured using western blotting confirmed that the addition of UO126 was sufficient in blocking all TGFbeta-induced ERK1/2 activation, as well as reducing Smad signaling at 18 h. Immunofluorescent labeling and further western blotting confirmed that TGFbeta-induced EMT was associated with an increase in alpha-smooth muscle actin (alpha-SMA) and a reduction of E-cadherin at cell borders.	U 0126	119-124	transforming growth factor beta 1	Homo sapiens	306-313	
28365272-7	2017	Pre-treatment with UO126 was effective at blocking the TGFbeta-induced EMT, as evidenced by a reduction of alpha-SMA expression and protein labeling, E-cadherin labeling at cell borders, and a reduction of cell loss, cell elongation and capsular wrinkling.	U 0126	19-24	transforming growth factor beta 1	Homo sapiens	55-62	
28365272-8	2017	Post-treatment with UO126 at 2 and 6 h after TGFbeta addition was also effective at blocking EMT while post-treatment with UO126 at 24 and 48 h was not sufficient in hampering TGFbeta-induced EMT.	U 0126	20-25	transforming growth factor beta 1	Homo sapiens	45-52	
26001858-10	2015	Pretreatment by U0126 and SB431542 effectively prevented the TGF-beta1-induced cell growth and collagen content in SCAPs.	U 0126	16-21	transforming growth factor beta 1	Homo sapiens	61-70	
26637807-8	2016	TGF-beta1-induced MMP-9 expression was decreased by both a MEK inhibitor, UO126, and a smad3 inhibitor, SIS3.	U 0126	74-79	transforming growth factor beta 1	Homo sapiens	0-9	
25882870-19	2015	However, the inhibition of Erk/Akt signaling pathways by U0126, a MEK-Erk inhibitor and LY294002, a PI3Kinase-Akt inhibitor, augmented TGF-beta1-induced apoptosis in OBA9 cells.	U 0126	57-62	transforming growth factor beta 1	Homo sapiens	135-144	
26001858-12	2015	U0126 prevented 0.5 ng/mL TGF-beta1-induced ALP activity but showed little effect on 10 ng/mL TGF-beta1-induced decline of ALP in SCAPs.	U 0126	0-5	transforming growth factor beta 1	Homo sapiens	26-35	
25446723-7	2015	In addition, we show that neurocan, aggrecan, and brevican levels are significantly reduced when TGFbeta is administered in the presence of either the PI3K inhibitor LY294002 or the mTOR inhibitor rapamycin, but not the MEK1/2 inhibitor U0126.	U 0126	237-242	transforming growth factor beta 1	Homo sapiens	97-104	
25482449-5	2015	Furthermore, TMEPAI gene activation by EGF and TGF-beta signaling was reduced by the MEK inhibitor U0126.	U 0126	99-104	transforming growth factor beta 1	Homo sapiens	47-55	
25428269-7	2015	Further, inhibition of Smad2 signalling using an inhibitor of activin receptor-linked kinase 5 SB431542 reduced TGF-beta1-induced Nox4 expression, while inhibition of ERK1/2 with the inhibitor of mitogen-activated protein kinase kinase 1/2 U0126 decreased both basal and TGF-beta1-induced Nox4 expression.	U 0126	240-245	transforming growth factor beta 1	Homo sapiens	112-121	
25428269-9	2015	Finally, TGF-beta1 enhanced endothelial cell proliferation, which was reduced by U0126 but not by SB431542.	U 0126	81-86	transforming growth factor beta 1	Homo sapiens	9-18	
24378341-6	2014	In addition, the mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) inhibitor, U0126, suppressed the osteogenic differentiation induced by TGF-beta alone.	U 0126	85-90	transforming growth factor beta 1	Homo sapiens	145-153	
24610459-9	2014	Moreover, TGF-beta1/FGF2-mediated EMT of HERS cells was reversed by the MEK1/2 inhibitor U0126.	U 0126	89-94	transforming growth factor beta 1	Homo sapiens	10-19	
25127907-8	2014	U0126 partly reversed this inhibitory effect of TGF-beta1.	U 0126	0-5	transforming growth factor beta 1	Homo sapiens	48-57	
24378341-7	2014	Moreover, U0126 completely suppressed the osteogenic differentiation synergistically induced by TGF-beta and PDGF, whereas the phosphoinositide-3-kinase (PI3K) inhibitor, LY294002, only partially suppressed this effect.	U 0126	10-15	transforming growth factor beta 1	Homo sapiens	96-104	
21718706-13	2011	Selective p44/42 kinase inhibitor UO126 successfully inhibited TGF-beta(1) production.	U 0126	34-39	transforming growth factor beta 1	Homo sapiens	63-74	
24113427-7	2014	Of these kinases, only the inhibition of ERK1/2 by U0126, which was a specific inhibitor of mitogen-activated protein kinase/ERK1/2, effectively blocked the TGF-beta1-induced expression of TIMP-1.	U 0126	51-56	transforming growth factor beta 1	Homo sapiens	157-166	
24203464-6	2014	Treatment with the MEK inhibitor U0126 followed by co-stimulation with EGF and TGF-beta1 prevented the upregulation of Snail protein, EMT and motility, without impairing Snail mRNA.	U 0126	33-38	transforming growth factor beta 1	Homo sapiens	79-88	
24383372-8	2013	ROS generation in response to TGF-beta1, measured as 2,7-dichlorofluorescein-diacetate fluorescence, was inhibited significantly by SB203580 and U0126, implicating both the p38 MAPK and Mekl/2/Erk1/2 signaling pathways.	U 0126	145-150	transforming growth factor beta 1	Homo sapiens	30-39	
22823995-13	2012	Interestingly, preincubation with mitogen-activated protein kinase (MAPK) cascade inhibitors U0126 (ERK pathway) and SB203580 (p38 pathway) decreased DIO3 mRNA levels and blocked the TGFbeta1-induced increase in DIO3 transcripts, suggesting that D3 induction might be mediated through the MAPK signaling pathway.	U 0126	93-98	transforming growth factor beta 1	Homo sapiens	183-191	
21713404-6	2012	In addition, EMT was reversed by PI3K inhibitor LY294002 and MEK1/2 inhibitor U0126, which suggested that A549 cells under stimulation of TGF-beta1 undergo a switch into mesenchymal cells and PI3K/Akt and MAPK/Erk1/2 signaling pathways serve to regulate TGF-beta1-induced EMT of A549 cells.	U 0126	78-83	transforming growth factor beta 1	Homo sapiens	138-147	
21880834-8	2011	Addition of the ERK1/2 signaling inhibitor U0126 was able to prevent the TGF-beta(1)-mediated increase in TER and claudin expression.	U 0126	43-48	transforming growth factor beta 1	Homo sapiens	73-83	
25700356-8	2014	Additionally, U0126, an ERK signaling inhibitor, exerted a reversible effect on TGF-beta1-induced EMT and inhibited FOXM1 expression.	U 0126	14-19	transforming growth factor beta 1	Homo sapiens	80-89	
22936401-8	2012	Treatment with SB203580 and U0126 reduced PLpro-induced expression of TGF-beta1, vimentin, and type I collagen.	U 0126	28-33	transforming growth factor beta 1	Homo sapiens	70-79	
22441145-3	2012	The effect of Ras/MEK/ERK pathway on TGF-beta-mediated Lefty up-regulation was tested by adding K-ras small interfering RNA, MEK inhibitor U0126, or extracellular signal-regulated kinase (ERK) inhibitor LY294002.	U 0126	139-144	transforming growth factor beta 1	Homo sapiens	37-45	
22037456-7	2011	TGF-beta-induced aberrant expression of class III beta-tubulin was significantly reduced by pretreatment with U0126, an inhibitor of ERK phosphorylation.	U 0126	110-115	transforming growth factor beta 1	Homo sapiens	0-8	
21282571-6	2011	The contribution of non-Smad signaling pathways to TGF-beta-induced alpha-SMA and PAI-1 expression was assessed using the small molecule inhibitors U0126 and LY294002.	U 0126	148-153	transforming growth factor beta 1	Homo sapiens	51-59	
21282571-9	2011	The MEK-inhibitor U0126 blocked TGF-beta-induced PAI-1 expression, whereas alpha-SMA expression was enhanced.	U 0126	18-23	transforming growth factor beta 1	Homo sapiens	32-40	
21131601-7	2011	In HaCaT and BJAB, two TGF-beta-sensitive cell lines, which had higher basal levels of phospho-MEK and TbetaRII compared with RL, U0126 induced downregulation of TbetaRII and blocked subsequent TGF-beta signaling.	U 0126	130-135	transforming growth factor beta 1	Homo sapiens	23-31	
21131601-7	2011	In HaCaT and BJAB, two TGF-beta-sensitive cell lines, which had higher basal levels of phospho-MEK and TbetaRII compared with RL, U0126 induced downregulation of TbetaRII and blocked subsequent TGF-beta signaling.	U 0126	130-135	transforming growth factor beta 1	Homo sapiens	194-202	
18023419-10	2008	Additionally, U0126, a specific inhibitor of ERK1/2, also significantly attenuated the TGF-beta1-stimulated VEGF synthesis.	U 0126	14-19	transforming growth factor beta 1	Homo sapiens	87-96	
18655827-8	2008	Furthermore, a MEK-specific inhibitor (U0126) abrogated BK-induced TGF-beta1 secretion, Smad2 phosphorylation, and alpha-SMA expression.	U 0126	39-44	transforming growth factor beta 1	Homo sapiens	67-76	
18218921-6	2008	This appears to be a direct effect of FGF signaling through mitogen-activated protein kinase (MAPK) cascades as the treatment of VICs with the MAPK/extracellular regulated kinase (MEK) inhibitor U0126 acted to induce fibrosis and blocked the ability of FGF-2 to inhibit TGF-beta1 signaling.	U 0126	195-200	transforming growth factor beta 1	Homo sapiens	270-279	
20962016-7	2010	HepG2 cells, otherwise resistant to TGF-beta1 killing due to high level of ERK1/2 activation, was sensitized by U0126, a specific MEK/ERK1/2 inhibitor, to TGF-beta1 cytotoxicity.	U 0126	112-117	transforming growth factor beta 1	Homo sapiens	36-45	
20962016-7	2010	HepG2 cells, otherwise resistant to TGF-beta1 killing due to high level of ERK1/2 activation, was sensitized by U0126, a specific MEK/ERK1/2 inhibitor, to TGF-beta1 cytotoxicity.	U 0126	112-117	transforming growth factor beta 1	Homo sapiens	155-164	
20553909-5	2010	However, TSA inhibited the TGF-beta1-induced phosphorylation of extracellular signal regulated kinase (ERK), and the MAPK/ERK kinase inhibitor U0126, which specifically inhibits ERK, also prevented TGF-beta1-induced apoptosis.	U 0126	143-148	transforming growth factor beta 1	Homo sapiens	198-207	
17409139-6	2007	Specific MEK1/2 inhibitors, flavenoid PD98059 and U0126, decreased the basal and TGF-beta1-stimulated Vp-1 expression by 95% or more.	U 0126	50-55	transforming growth factor beta 1	Homo sapiens	81-90	
18571460-4	2008	Furthermore, the Ang II-induced TGF-beta1 secretion, alpha-SMA expression, and delayed phosphorylation of Smad2 in hADSCs were abrogated by the MEK inhibitor U0126, suggesting a pivotal role of MEK/ERK pathway in the Ang II-induced activation of TGF-beta1-Smad2 signaling pathway.	U 0126	158-163	transforming growth factor beta 1	Homo sapiens	32-41	
18571460-4	2008	Furthermore, the Ang II-induced TGF-beta1 secretion, alpha-SMA expression, and delayed phosphorylation of Smad2 in hADSCs were abrogated by the MEK inhibitor U0126, suggesting a pivotal role of MEK/ERK pathway in the Ang II-induced activation of TGF-beta1-Smad2 signaling pathway.	U 0126	158-163	transforming growth factor beta 1	Homo sapiens	246-255	
16141544-5	2005	ERK inhibitor, U0126 completely prevented TGF-beta production.	U 0126	15-20	transforming growth factor beta 1	Homo sapiens	42-50	
17096210-8	2007	Pretreatment with U0126, an inhibitor of ERK1/2, significantly enhanced the TGF-beta1-mediated antiproliferative and apoptosis induction effects in BEP2D cells.	U 0126	18-23	transforming growth factor beta 1	Homo sapiens	76-85	
17209135-4	2007	The induction of elastin hnRNA and mRNA expression by TGF-beta was abolished by pretreatments with TGF-beta receptor I inhibitor, global transcription inhibitor actinomycin D, and partially blocked by addition of protein synthesis inhibitor cycloheximide, but was not affected by the p44/42 MAPK inhibitor U0126.	U 0126	306-311	transforming growth factor beta 1	Homo sapiens	54-62	
17313766-5	2006	RESULTS: (1) the production in 15 and 25 micromol/L U0126 incubated groups was (87 +/- 11) pg/ml and (75 +/- 19) pg/ml respectively, which was significantly decreased compared with that in 10(-7) mol/L ALDO incubated group (P < 0.05), however, the amount of TGF-beta1 in these groups were still significant higher than that in the control group (P < 0.05).	U 0126	52-57	transforming growth factor beta 1	Homo sapiens	261-270	
16139919-4	2005	RESULTS: The phophatidylinositol 3-kinase (PI3K) inhibitor LY294002 and the mitogen-activated protein kinase inhibitor, UO126, decreased the TGF-beta1-dependent ADAM12 expression and prevented the phosphorylation of p70S6K.	U 0126	120-125	transforming growth factor beta 1	Homo sapiens	141-150	
15956343-16	2005	However, TGF-beta even in MCC-DNTbetaRII cells induced ERK1/2 phosphorylation, and treatment with MEK inhibitor, UO126, inhibited the antagonistic effects of TGF-beta on IGFBP-3.	U 0126	113-118	transforming growth factor beta 1	Homo sapiens	158-166	
15963850-6	2005	The farnesyl transferase inhibitor L744832 and the MEK inhibitor U0126 both restored p27 levels and cell-cycle arrest in response to TGF-beta.	U 0126	65-70	transforming growth factor beta 1	Homo sapiens	133-141	
16123076-6	2005	The effect of TGF-beta and GnRHa on FMOD expression was reversed following pretreatment of LSMC and MSMC with Smad3 SiRNA and U0126 (MEK1/2 inhibitor), respectively.	U 0126	126-131	transforming growth factor beta 1	Homo sapiens	14-22	
15956343-17	2005	Furthermore, UO126 blocked the TGF-beta inhibition of STAT-1 phosphorylation induced by IGFBP-3.	U 0126	13-18	transforming growth factor beta 1	Homo sapiens	31-39	
15468069-5	2005	Inhibitors of this pathway, PD98059 and U0126, downregulated TGF-beta-induced expression of TIMP-3 RNA and protein.	U 0126	40-45	transforming growth factor beta 1	Homo sapiens	61-69	
15265761-8	2004	Pretreatment with U-0126, a MEK1/2 inhibitor, blocked basal, as well as GnRHa- and TGF-beta1-induced pERK1/2; however, it differentially affected c-fos, c-jun, and fibronectin expression.	U 0126	18-24	transforming growth factor beta 1	Homo sapiens	83-92	
15537865-7	2005	Finally, inhibition of MAP kinase signaling, using the selective inhibitor U0126, promoted FSH-R expression and further enhanced TGF beta1-induced FSH-R expression in vitro.	U 0126	75-80	transforming growth factor beta 1	Homo sapiens	129-138	
12717386-7	2003	The PI3K inhibitor LY294002 and the mitogen-activated protein kinase kinase (MEK) inhibitor UO126 prevented ADAM12 induction by TGF-beta, suggesting the involvement of PI3K and MEK activities.	U 0126	92-97	transforming growth factor beta 1	Homo sapiens	128-136	
15531510-4	2004	GnRHa and TGF-beta increased ERK1/2 nuclear accumulation resulting in differential regulation of c-fos and c-jun mRNA expression via downstream signaling from MAPK kinase (MEK)1/2, because pretreatment with U0126, a synthetic inhibitor of MEK1/2, abolished basal and GnRHa- and TGF-beta-induced pERK1/2 and the expression of c-fos and c-jun.	U 0126	207-212	transforming growth factor beta 1	Homo sapiens	10-18	
15531510-4	2004	GnRHa and TGF-beta increased ERK1/2 nuclear accumulation resulting in differential regulation of c-fos and c-jun mRNA expression via downstream signaling from MAPK kinase (MEK)1/2, because pretreatment with U0126, a synthetic inhibitor of MEK1/2, abolished basal and GnRHa- and TGF-beta-induced pERK1/2 and the expression of c-fos and c-jun.	U 0126	207-212	transforming growth factor beta 1	Homo sapiens	278-286	
14726474-8	2004	Lastly, BNP stimulated the extracellular signal-related kinase pathway via cyclic guanosine monophosphate-dependent protein kinase signaling, and two mitogen-activated protein kinase kinase inhibitors, U0126 and PD98059, reversed BNP inhibition of TGF-beta-induced collagen-1 expression.	U 0126	202-207	transforming growth factor beta 1	Homo sapiens	248-256	
14751283-7	2004	TGF-beta1-mediated NF-kappabeta activation was blocked by wortmannin and U0126, indicating the involvement of both phosphatidylinositol-3-OH kinase (PI3k)/Akt and mitogen-activated protein kinase (MAPK)/extracellular-signal regulated kinase (Erk)1,2 pathways in the action of TGF-beta1.	U 0126	73-78	transforming growth factor beta 1	Homo sapiens	0-9	
14751283-7	2004	TGF-beta1-mediated NF-kappabeta activation was blocked by wortmannin and U0126, indicating the involvement of both phosphatidylinositol-3-OH kinase (PI3k)/Akt and mitogen-activated protein kinase (MAPK)/extracellular-signal regulated kinase (Erk)1,2 pathways in the action of TGF-beta1.	U 0126	73-78	transforming growth factor beta 1	Homo sapiens	276-285	
14751283-10	2004	Of note, wortmannin and U0126, as well as kappabeta-decoy DNA, abolished the anti-apoptotic effect of TGF-beta1, corroborating the notion that both PI3k/Akt and MAPK/Erk1,2 pathways, and NF-kappabeta activity are necessary for the anti-apoptotic activity of TGF-beta1.	U 0126	24-29	transforming growth factor beta 1	Homo sapiens	102-111	
15192088-10	2004	When an inhibitor of MAPK (U0126) was used, the TGF-beta-mediated proliferative response in HeLa cells was completely abolished.	U 0126	27-32	transforming growth factor beta 1	Homo sapiens	48-56	
15044465-7	2004	TGF-beta-induced motility was blocked by coincubation with either the phosphatidylinositol 3-kinase inhibitor LY294002, the mitogen-activated protein kinase (MAPK) inhibitor U0126, the p38 MAPK inhibitor SB202190, and an integrin beta(1) blocking antibody.	U 0126	174-179	transforming growth factor beta 1	Homo sapiens	0-8	
14566975-8	2003	VEGF mRNA levels and protein secretion induced by TGF-beta were significantly inhibited by SB203580 and U0126, inhibitors of MAP kinases, but not by staurosporine and PDTC, protein kinase C and NF-kappaB pathway inhibitors, respectively.	U 0126	104-109	transforming growth factor beta 1	Homo sapiens	50-58	
12441075-6	2002	U0126, a specific inhibitor of MEK, suppressed TGF-beta 1-mediated ERK 1/2 phosphorylation and p21 induction in HSC-39 cells and constitutive ERK 1/2 phosphorylation in GT38 cells.	U 0126	0-5	transforming growth factor beta 1	Homo sapiens	47-57	
11500937-5	2001	We confirmed that PD98059 or U0126 did actually suppress the phosphorylation of p42/p44 MAP kinase by TGF-beta in our preparations.	U 0126	29-34	transforming growth factor beta 1	Homo sapiens	102-110	
11741826-3	2002	ERK1/2 phosphorylation increased threefold above the control level, and the increase was temporally associated with the increase in MLC-P. Inhibition of ERK1/2 phosphorylation with the MAPK kinase inhibitor U-0126 did not prevent the increase in either monolayer permeability or MLC-P. p38 MAPK phosphorylation increased fourfold above the control level, but unlike ERK1/2, this increase peaked 30 min and 1 h post-TGF-beta1 treatment.	U 0126	207-213	transforming growth factor beta 1	Homo sapiens	415-424	
11978861-6	2002	TGF-beta1-treated sensory neurons showed a significant reduction in the number of these puncta, an effect that was blocked by the MAP/ERK kinase inhibitor U0126.	U 0126	155-160	transforming growth factor beta 1	Homo sapiens	0-9	
34003249-7	2021	SGLT2 and ERK inhibition on D-glucose, 25mM, and TGF-beta1, 0.75ng/ml, treated cells was explored using dapagliflozin and U0126, respectively.	U 0126	122-127	transforming growth factor beta 1	Homo sapiens	49-58